查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602117

生長抑制素類似物市場：按類型、按應用分類 - 全球預測 2025-2030

Somatostatin Analogs Market by Type (Lanreotide, Octreotide, Pasireotide), Application (Acromegaly, Neuroendocrine Tumors) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

生長抑制素類似物市場2023年估值為68億美元，預計2024年將達到74.9億美元，複合年成長率為10.32%，預計到2030年將達到135.2億美元。

生長抑制素類似物是天然荷爾蒙生長抑制素的合成版本，主要用於醫療環境中治療肢端肥大症、神經內分泌腫瘤和某些胃腸道疾病等疾病。這些類似物的需求是因為它們能夠調節內分泌系統並抑制各種輔助荷爾蒙的分泌，這使得它們在治療荷爾蒙分泌腫瘤中至關重要。生長抑制素類似物在腫瘤學和內分泌學中具有重要應用，對於最佳化荷爾蒙調節至關重要的患者預後至關重要。最終用途廣泛，包括醫院、專科診所和研究機構。由於給藥系統的技術進步、個人化醫療的趨勢以及全球目標疾病盛行率的增加，該市場有望成長。影響成長的主要因素包括老化社會的人口變化以及疾病早期診斷和管理意識的提高。

主要市場統計
基準年[2023] 68億美元
預測年份 [2024] 74.9億美元
預測年份 [2030] 135.2億美元
複合年成長率（%） 10.32%

藥物配方和生長抑制素類似物緩釋變異體的持續創新凸顯了新的商機，這些創新有望改善患者的依從性和治療結果。生物相似藥的出現也提供了具有成本效益的解決方案並擴大了治療的機會。然而，治療成本上升、嚴格監管以及長期使用潛在副作用等挑戰正在阻礙市場成長。藥物傳遞的創新將在提高藥物生物有效性、開發經皮貼片和植入裝置等新型輸送機制以及透過可能將精準醫療與人工智慧相結合來提高治療準確性等領域取得進展。

瞄準這一市場的公司可能會受益於投資下一代配方的研發或與生技公司合作。監管合規性和對專利格局的了解對於保持競爭優勢至關重要。由於市場受到專利到期和生物相似藥進入的影響，保持產品創新和多樣化至關重要。市場競爭仍然激烈，跨國製藥巨頭和新興生物技術公司都專注於利基治療領域，推動市場發展。

市場動態：揭示快速發展的生長抑制素類似物市場的關鍵市場洞察

生長抑制素類似物市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 庫欣氏症候群、肢端肥大症和其他相關疾病的發生率增加
    • 全球罕見疾病藥物研發支出
    • 對罕見疾病患者有利的政府政策和製度
  • 市場限制因素
    • 由於大量未確診患者導致意識下降
  • 市場機會
    • 新藥上市的研發進展
    • 製藥公司與研究公司的策略聯盟
  • 市場挑戰
    • 肢端肥大症等疾病的替代治療方法的可用性

波特的五力：駕馭生長抑制素類似物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解生長抑制素類似物市場的外在影響

外部宏觀環境因素在塑造生長抑制素類似物市場的表現動態中發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解生長抑制素類似物市場的競爭格局

對生長抑制素類似物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣生長抑制素類似物市場供應商的績效評估

FPNV 定位矩陣是評估生長抑制素類似物市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。四個象限清楚且準確地分類了供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 庫欣氏症候群、肢端肥大症和其他相關疾病的發生率增加
      • 全球正在投入巨額資金來開發治療罕見疾病的藥物。
      • 對罕見疾病患者有利的政府政策和製度
    • 抑制因素
      • 由於意識下降，未確診患者的數量正在增加。
    • 機會
      • 持續進行新藥發布的研發活動
      • 製藥公司與研究公司之間的策略合作
    • 任務
      • 肢端肥大症等疾病的替代治療方法的可用性
  • 市場區隔分析
    • 類型：Octreotide因其安全性和有效性而越來越受到青睞
    • 用途：利用生長抑制素類似物治療肢端肥大症，因為其效力高且半衰期長。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章生長抑制素類似物市場：依類型

  • Lanreotide
  • Octreotide
  • 蝶形科

第7章生長抑制素類似物市場：依應用

  • 肢端肥大症
  • 神經內分泌腫瘤

第8章美洲生長抑制素類似物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區生長抑制素類似物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲生長抑制素類似物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • FDA 已選擇 RayzeBio 參與第一個 CDRP 計劃，以加速 GEP-NET 上 RYZ101 的商業生產準備。
    • Ipsen 宣布投資 Somatulin Autogel/Somatulin Depot (Lanreotide) 新型電子自動注射器，旨在改善病患體驗
    • 歐盟委員會核准mycapsa 用於治療肢端肥大症

公司名單

  • Viatris Inc.
  • Wockhardt Ltd.
  • Bachem AG
  • Novartis AG
  • Hybio Pharmaceutical Co., Ltd.
  • Fresenius SE & Co. KGaA
  • MedKoo Biosciences, Inc.
  • Recordati Rare Diseases, Inc.
  • Dauntless Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Merck KGaA
  • Teva Pharmaceutical Industries Ltd.
  • Ipsen Pharma
  • CVS Health Corporation
  • Abbiotec, Inc.
  • Peptron, Inc.
  • Camurus AB
  • Advanz Pharma Corp.
  • Crinetics Pharmaceuticals, Inc.
  • Pharmascience Inc.
  • Biodexa Pharmaceuticals PLC
  • Cipla Limited
  • Amryt Pharma PLC by Chiesi Farmaceutici SpA
  • Teijin Limited
  • Sun Pharmaceutical Industries Limited
Product Code: MRR-2214614773A1

The Somatostatin Analogs Market was valued at USD 6.80 billion in 2023, expected to reach USD 7.49 billion in 2024, and is projected to grow at a CAGR of 10.32%, to USD 13.52 billion by 2030.

Somatostatin analogs are synthetic versions of the naturally occurring hormone somatostatin, utilized primarily in medical settings to manage diseases such as acromegaly, neuroendocrine tumors, and certain gastrointestinal disorders. The necessity of these analogs stems from their ability to regulate the endocrine system and inhibit the secretion of various secondary hormones, making them pivotal in treating hormone-secreting tumors. With applications primarily in oncology and endocrinology, somatostatin analogs are indispensable in optimizing patient outcomes where hormone regulation is crucial. End-use scope spans across hospitals, specialty clinics, and research institutions. The market is poised for growth due to technological advancements in drug delivery systems, personalized medicine trends, and an increasing global prevalence of target diseases. Key factors influencing growth include demographic shifts towards an aging population and rising awareness about early disease diagnosis and management.

KEY MARKET STATISTICS
Base Year [2023] USD 6.80 billion
Estimated Year [2024] USD 7.49 billion
Forecast Year [2030] USD 13.52 billion
CAGR (%) 10.32%

Emerging opportunities are highlighted by ongoing innovations in drug formulation and extended-release variants of somatostatin analogs, which promise better patient compliance and outcomes. The advent of biosimilars also offers cost-effective solutions, widening access to treatments. However, market growth is challenged by factors such as high treatment costs, stringent regulatory pathways, and potential side effects associated with long-term use. Innovation can thrive in areas such as enhancing drug bioavailability, developing novel delivery mechanisms like transdermal patches or implantable devices, and integrating AI-driven precision medicine to tailor treatments more accurately.

For businesses aiming to capitalize on this market, investing in R&D for next-gen drug formulations and securing partnerships with biotech companies can be advantageous. Regulatory compliance and navigating patent landscapes are critical to maintaining competitive advantage. As the market is shaped by patent expirations and the entrance of biosimilars, maintaining innovation and diversification in product offerings will be essential. The nature of the market remains highly competitive, driven by both multinational pharmaceutical giants and emerging biotech firms focusing on niche therapeutic areas.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Somatostatin Analogs Market

The Somatostatin Analogs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing Incidence of Cushing Syndrome, Acromegaly and Other Associated Diseases
    • Extensive Spending on Development of Drugs for Rare Diseases Globally
    • Favorable Government Policies and Schemes for Patients with Rare Diseases
  • Market Restraints
    • Reduced Awareness Resulting in a High Number of Undiagnosed Patients
  • Market Opportunities
    • Ongoing Research and Development Activities for the Launch of Novel Drug Therapeutics
    • Strategic Collaboration Among Pharmaceutical and Research Companies
  • Market Challenges
    • Availability of Alternative Treatment Methods for Diseases Such as Acromegaly

Porter's Five Forces: A Strategic Tool for Navigating the Somatostatin Analogs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Somatostatin Analogs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Somatostatin Analogs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Somatostatin Analogs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Somatostatin Analogs Market

A detailed market share analysis in the Somatostatin Analogs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Somatostatin Analogs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Somatostatin Analogs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Somatostatin Analogs Market, highlighting leading vendors and their innovative profiles. These include Viatris Inc., Wockhardt Ltd., Bachem AG, Novartis AG, Hybio Pharmaceutical Co., Ltd., Fresenius SE & Co. KGaA, MedKoo Biosciences, Inc., Recordati Rare Diseases, Inc., Dauntless Pharmaceuticals, Inc., Pfizer Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Ipsen Pharma, CVS Health Corporation, Abbiotec, Inc., Peptron, Inc., Camurus AB, Advanz Pharma Corp., Crinetics Pharmaceuticals, Inc., Pharmascience Inc., Biodexa Pharmaceuticals PLC, Cipla Limited, Amryt Pharma PLC by Chiesi Farmaceutici S.p.A., Teijin Limited, and Sun Pharmaceutical Industries Limited.

Market Segmentation & Coverage

This research report categorizes the Somatostatin Analogs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Lanreotide, Octreotide, and Pasireotide.
  • Based on Application, market is studied across Acromegaly and Neuroendocrine Tumors.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing Incidence of Cushing Syndrome, Acromegaly and Other Associated Diseases
      • 5.1.1.2. Extensive Spending on Development of Drugs for Rare Diseases Globally
      • 5.1.1.3. Favorable Government Policies and Schemes for Patients with Rare Diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Reduced Awareness Resulting in a High Number of Undiagnosed Patients
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing Research and Development Activities for the Launch of Novel Drug Therapeutics
      • 5.1.3.2. Strategic Collaboration Among Pharmaceutical and Research Companies
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of Alternative Treatment Methods for Diseases Such as Acromegaly
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing preference for octreotide due to its safety and efficacy
    • 5.2.2. Application: Utilization of somatostatin analogs for the treatment of acromegaly due to their greater potency and longer half life
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Somatostatin Analogs Market, by Type

  • 6.1. Introduction
  • 6.2. Lanreotide
  • 6.3. Octreotide
  • 6.4. Pasireotide

7. Somatostatin Analogs Market, by Application

  • 7.1. Introduction
  • 7.2. Acromegaly
  • 7.3. Neuroendocrine Tumors

8. Americas Somatostatin Analogs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Somatostatin Analogs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Somatostatin Analogs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. FDA selects RayzeBio to Participate in the Inaugural CDRP Program to Expedite Commercial Manufacturing Readiness for RYZ101 in GEP-NETs
    • 11.3.2. Ipsen announces investment in new electronic autoinjector for Somatuline Autogel / Somatuline Depot (lanreotide) designed to improve patient experience
    • 11.3.3. European Commission approves Mycapssa for the treatment of Acromegaly

Companies Mentioned

  • 1. Viatris Inc.
  • 2. Wockhardt Ltd.
  • 3. Bachem AG
  • 4. Novartis AG
  • 5. Hybio Pharmaceutical Co., Ltd.
  • 6. Fresenius SE & Co. KGaA
  • 7. MedKoo Biosciences, Inc.
  • 8. Recordati Rare Diseases, Inc.
  • 9. Dauntless Pharmaceuticals, Inc.
  • 10. Pfizer Inc.
  • 11. Merck KGaA
  • 12. Teva Pharmaceutical Industries Ltd.
  • 13. Ipsen Pharma
  • 14. CVS Health Corporation
  • 15. Abbiotec, Inc.
  • 16. Peptron, Inc.
  • 17. Camurus AB
  • 18. Advanz Pharma Corp.
  • 19. Crinetics Pharmaceuticals, Inc.
  • 20. Pharmascience Inc.
  • 21. Biodexa Pharmaceuticals PLC
  • 22. Cipla Limited
  • 23. Amryt Pharma PLC by Chiesi Farmaceutici S.p.A.
  • 24. Teijin Limited
  • 25. Sun Pharmaceutical Industries Limited

LIST OF FIGURES

  • FIGURE 1. SOMATOSTATIN ANALOGS MARKET RESEARCH PROCESS
  • FIGURE 2. SOMATOSTATIN ANALOGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. SOMATOSTATIN ANALOGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. SOMATOSTATIN ANALOGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SOMATOSTATIN ANALOGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SOMATOSTATIN ANALOGS MARKET DYNAMICS
  • TABLE 7. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY LANREOTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY OCTREOTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PASIREOTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ACROMEGALY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM SOMATOSTATIN ANALOGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. SOMATOSTATIN ANALOGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 101. SOMATOSTATIN ANALOGS MARKET, FPNV POSITIONING MATRIX, 2023